Close Menu

NEW YORK ─ Kephera Diagnostics said on Thursday that it has been awarded a two-year, $2 million Phase II Small Business Innovation Research grant by the National Institute of Allergy and Infectious Diseases to complete the development and launch of a test for Zika virus infection.

The Framingham, Massachusetts-based firm said that the grant will enable it to complete the development of its Zika virus test and conduct the clinical validations needed for approval from the US Food and Drug Administration and other regulatory agencies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.